Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been assigned an average rating of “Hold” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $5.00.

A number of equities research analysts have recently commented on GOSS shares. Wedbush reaffirmed a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. Wall Street Zen cut shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Leerink Partners cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd. Finally, HC Wainwright dropped their price target on shares of Gossamer Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 6th.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in Gossamer Bio by 66.5% in the 1st quarter. Bank of America Corp DE now owns 3,173,725 shares of the company’s stock valued at $1,041,000 after acquiring an additional 1,267,056 shares during the period. ADAR1 Capital Management LLC grew its stake in Gossamer Bio by 233.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 287,531 shares of the company’s stock valued at $94,000 after acquiring an additional 503,100 shares during the period. Kalehua Capital Management LLC acquired a new stake in Gossamer Bio in the 1st quarter valued at $3,363,000. Renaissance Technologies LLC grew its stake in Gossamer Bio by 84.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,217,868 shares of the company’s stock valued at $400,000 after acquiring an additional 558,980 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in Gossamer Bio in the 1st quarter valued at $38,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $0.21 on Monday. The stock has a market capitalization of $49.31 million, a price-to-earnings ratio of -0.27 and a beta of 2.15. Gossamer Bio has a 12 month low of $0.16 and a 12 month high of $3.87. The firm’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $1.75.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Monday, May 18th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $16.96 million for the quarter, compared to analyst estimates of $4.67 million. Analysts anticipate that Gossamer Bio will post -0.46 earnings per share for the current fiscal year.

Gossamer Bio News Summary

Here are the key news stories impacting Gossamer Bio this week:

• Negative Sentiment: Multiple law firms, including Frank R. Cruz, Faruqi & Faruqi, Rosen, Pomerantz, Bronstein Gewirtz & Grossman, and Schall, published reminders and investor alerts about an already filed securities fraud class action against Gossamer Bio. Article: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The lawsuits center on allegations related to the February 23, 2026 disclosure that top-line Phase 3 PROSERA results failed to meet the primary endpoint, a development that can increase uncertainty around the company’s pipeline and future value. Article: Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS
• Neutral Sentiment: Several notices highlight a June 1, 2026 lead-plaintiff deadline for investors who bought GOSS shares during the class period, adding to the near-term legal spotlight but not changing the scientific or operational outlook by itself. Article: GOSS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.